X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs TORRENT PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS TORRENT PHARMA IPCA LABS/
TORRENT PHARMA
 
P/E (TTM) x 38.8 29.0 133.7% View Chart
P/BV x 3.0 5.5 53.9% View Chart
Dividend Yield % 0.2 1.0 17.5%  

Financials

 IPCA LABS   TORRENT PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
TORRENT PHARMA
Mar-17
IPCA LABS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6431,768 36.4%   
Low Rs5031,186 42.4%   
Sales per share (Unadj.) Rs254.4346.1 73.5%  
Earnings per share (Unadj.) Rs16.155.2 29.1%  
Cash flow per share (Unadj.) Rs29.873.3 40.6%  
Dividends per share (Unadj.) Rs1.0014.00 7.1%  
Dividend yield (eoy) %0.20.9 18.4%  
Book value per share (Unadj.) Rs194.6257.1 75.7%  
Shares outstanding (eoy) m126.20169.22 74.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.3 52.8%   
Avg P/E ratio x35.726.8 133.2%  
P/CF ratio (eoy) x19.220.1 95.5%  
Price / Book Value ratio x2.95.7 51.3%  
Dividend payout %6.225.4 24.5%   
Avg Mkt Cap Rs m72,300249,887 28.9%   
No. of employees `00013.311.8 112.9%   
Total wages/salary Rs m6,9609,934 70.1%   
Avg. sales/employee Rs Th2,413.54,971.5 48.5%   
Avg. wages/employee Rs Th523.2843.2 62.0%   
Avg. net profit/employee Rs Th152.4792.4 19.2%   
INCOME DATA
Net Sales Rs m32,10658,569 54.8%  
Other income Rs m2262,233 10.1%   
Total revenues Rs m32,33260,802 53.2%   
Gross profit Rs m4,44813,773 32.3%  
Depreciation Rs m1,7303,069 56.4%   
Interest Rs m2412,056 11.7%   
Profit before tax Rs m2,70310,881 24.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6751,545 43.7%   
Profit after tax Rs m2,0289,336 21.7%  
Gross profit margin %13.923.5 58.9%  
Effective tax rate %25.014.2 175.9%   
Net profit margin %6.315.9 39.6%  
BALANCE SHEET DATA
Current assets Rs m17,34053,841 32.2%   
Current liabilities Rs m9,55931,612 30.2%   
Net working cap to sales %24.238.0 63.9%  
Current ratio x1.81.7 106.5%  
Inventory Days Days10097 103.2%  
Debtors Days Days5784 67.9%  
Net fixed assets Rs m20,77942,079 49.4%   
Share capital Rs m252846 29.8%   
"Free" reserves Rs m24,49942,655 57.4%   
Net worth Rs m24,55343,501 56.4%   
Long term debt Rs m3,51722,408 15.7%   
Total assets Rs m39,595101,250 39.1%  
Interest coverage x12.26.3 194.3%   
Debt to equity ratio x0.10.5 27.8%  
Sales to assets ratio x0.80.6 140.2%   
Return on assets %5.711.3 50.9%  
Return on equity %8.321.5 38.5%  
Return on capital %10.519.6 53.4%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571NA-   
Fx inflow Rs m15,61720,066 77.8%   
Fx outflow Rs m5,8285,304 109.9%   
Net fx Rs m9,79014,762 66.3%   
CASH FLOW
From Operations Rs m2,76410,127 27.3%  
From Investments Rs m-1,432-7,869 18.2%  
From Financial Activity Rs m-1,591-1,918 83.0%  
Net Cashflow Rs m-259212 -122.4%  

Share Holding

Indian Promoters % 45.9 71.5 64.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 7.0 162.4%  
FIIs % 25.3 12.6 200.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.8 197.7%  
Shareholders   36,892 26,511 139.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 19, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS